Emergent BioSolutions (EBS) Other Accumulated Expenses (2018 - 2026)

Emergent BioSolutions' Other Accumulated Expenses history runs 9 years deep, the most recent figure standing at $8.0 million for Q1 2026.

• In Q1 2026, Other Accumulated Expenses fell 27.93% year-over-year to $8.0 million; the TTM figure through Mar 2026 stood at $8.0 million (down 27.93% YoY), while the FY2025 annual figure was $10.8 million, down 50.68% from the prior year.
• Other Accumulated Expenses was $8.0 million for Q1 2026 at Emergent BioSolutions, down from $10.8 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $67.6 million in Q3 2024 to a low of $8.0 million in Q1 2026.
• Historically, Other Accumulated Expenses has averaged $25.3 million across 5 years, with a median of $24.1 million in 2025.
• The sharpest annual moves came in 2022 and 2024: Other Accumulated Expenses tumbled 79.84% in 2022, then jumped 76.96% in 2024.
• A 5-year view of Other Accumulated Expenses shows it stood at $45.9 million in 2022, then fell by 28.76% to $32.7 million in 2023, then tumbled by 33.03% to $21.9 million in 2024, then sank by 50.68% to $10.8 million in 2025, then fell by 25.93% to $8.0 million in 2026.
• The last three Other Accumulated Expenses figures came in at $8.0 million (Q1 2026), $10.8 million (Q4 2025), and $24.1 million (Q3 2025), per Business Quant data.